Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours.
暂无分享,去创建一个
Jürgen Hennig | Eric Masson | Yu-Yun Ho | Bruno Morgan | J. Hennig | J. Drevs | D. Marmé | D. Lebwohl | C. Unger | B. Morgan | Klaus Mross | M. Medinger | E. Masson | K. Mross | Dirk Laurent | Michael Medinger | Joachim Drevs | Dieter Marmé | Clemens Unger | Clemens Günther | David Lebwohl | Marianne Müller | D. Laurent | Y. Ho | M. Müller | C. Günther
[1] J. Folkman. Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.
[2] E. Rostrup,et al. Myocardial perfusion modeling using MRI , 1996, Magnetic resonance in medicine.
[3] N. Ferrara,et al. Molecular and biological properties of the vascular endothelial growth factor family of proteins. , 1992, Endocrine reviews.
[4] J. Hennig,et al. PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. , 2002, Cancer research.
[5] F. Scappaticci. Mechanisms and future directions for angiogenesis-based cancer therapies. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] L. Liotta,et al. Tumor invasion and metastases: biochemical mechanisms. , 1988, Cancer treatment and research.
[7] K. Mross. Anti-angiogenesis therapy:concepts and importance of dosing schedules in clinical trials. , 2000, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[8] J. Aldrich,et al. Tumour blood flow: measurement and manipulation for therapeutic gain. , 1993, Cancer treatment reviews.
[9] S. Fan,et al. Clinical Significance of Angiogenesis in Gastrointestinal Cancers: A Target for Novel Prognostic and Therapeutic Approaches , 2003, Annals of surgery.
[10] R. Labianca,et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer , 1998, The Lancet.
[11] Lars Holmgren,et al. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression , 1995, Nature Medicine.
[12] G. Neufeld,et al. Vascular endothelial growth factor (VEGF) and its receptors , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[13] H. Dvorak,et al. Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. , 1997, EXS.
[14] J. Drevs,et al. Antiangiogenesis: Current Clinical Data and Future Perspectives , 2002, Oncology Research and Treatment.
[15] Stephanie Green,et al. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria , 1992, Investigational New Drugs.
[16] J. Mestan,et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. , 2000, Cancer research.
[17] Brygida Berse,et al. Vascular permeability factor (VPF, VEGF) in tumor biology , 1993, Cancer and Metastasis Reviews.
[18] D. Hanahan,et al. Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.
[19] J. Wood,et al. Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.